Objective: To observe the clinical efficacy of traditional Chinese medicine(TCM) directing therapy in the treatment of pelvic inflammatory disease sequelae (SPID) with the syndrome of Qi stagnation and blood stasis. Methods: From April 2016 to April 2018, 60 patients of SPID with the syndrome of Qi stagnation and blood stasis in the Traditional Chinese Medicine Hospital of Pudong New Area of Shanghai were randomly divided into the treatment group and the control group according to the digital table, with 30 cases in each group.The control group was treated with FukeQianjin capsules, and the treatment group was treated with TCM directing therapy, with a course of 1 month.The clinical efficacy was observed, and the TCM syndrome score and gynecological examination score were compared. Results: The total effective rate of the treatment group was 96.67%(29/30), which was significantly higher than 80.00%(24/30) of the control group (χ²=4.043, P<0.05). The gynecological examination score of the control group after treatment was (8.87±3.26)points, which was significantly lower than that before treatment [(16.50±5.35)points] (t=9.34, P<0.05). The gynecological examination score of the treatment group after treatment was (6.47±3.19)points, which was significantly lower than that before treatment [(17.83±4.47)points](t=10.92, P<0.05). The TCM syndrome score of the control group after treatment was (11.33±4.18)points, which was significantly lower than that before treatment [(26.33±7.61)points](t=9.99, P<0.05). The TCM syndrome score of the treatment group after treatment was (8.93±3.74)points, which was significantly lower than that before treatment [(29.67±7.61)points](t=13.37, P<0.05). After treatment, the decrease of TCM syndrome score in the treatment group was obviously better than that in the control group (t=2.23, P<0.05). And the decrease of the gynecological examination score in the treatment group was obviously better than that in the control group(t=2.50, P<0.05). Conclusion TCM directing therapy has good efficacy in the treatment of SPID with the syndrome of Qi stagnation and blood stasis.